No significant sex- or weight-based risks were noted for liraglutide or tirzepatide
Originally developed for Type 2 diabetes, these medications have gained FDA approval for obesity, reducing risk for heart disease and kidney disease, and treatment of obstructive sleep apnea within the last three years
Reduce to a lower dose
Its levels vary throughout the body, reaching up to 10 mM in liver cells while other cells maintain millimolar concentrations
Similarly, there was some lack of consistency in 1 H-MRS approach and measurement, although this did not adversely affect our ability to compare across studies
Weight loss results may vary among individuals depending on body mass index, genetics, lifestyle, dietary habits, and physical activity